COM:4DMOLECULARTHERAPEUTICS
4D Molecular Therapeutics Inc
- Stock
Last Close
7.99
22/11 21:00
Market Cap
269.97M
Beta: -
Volume Today
2.60K
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|
net income | -11.22M - | -9.55M 14.90% | -49.31M 416.24% | -56.69M 14.98% | -71.32M 25.80% | -107.49M 50.73% | -100.84M 6.19% | |
depreciation and amortization | 626K - | 697K 11.34% | 1.00M 44.05% | 1.44M 43.73% | 3.02M 109.29% | 3.88M 28.48% | 5.75M 48.17% | |
deferred income tax | 2.65M - | 20K 99.25% | -896K - | |||||
stock based compensation | 256K - | 1.38M 437.89% | 3.54M 157.15% | 4.98M 40.75% | 13.80M 176.87% | 17.12M 24.07% | 19.66M 14.86% | |
change in working capital | 18.54M - | -8.78M 147.34% | 259K 102.95% | -711K 374.52% | -15.53M 2,084.81% | -1.34M 91.40% | 630K 147.16% | |
accounts receivables | -320K - | -803K 150.94% | 146K 118.18% | -508K 447.95% | 1.44M 383.27% | 47K 96.73% | ||
inventory | -53K - | 175K 430.19% | 2.93M 1,572% | -591K 120.20% | -4.54M 667.51% | |||
accounts payables | -114K - | 438K 484.21% | 533K 21.69% | 43K 91.93% | 2.29M 5,213.95% | -1.64M 171.68% | 896K 154.70% | |
other working capital | 19.03M - | -8.59M 145.13% | -3.35M 61.03% | 345K 110.31% | -14.72M 4,367.25% | 255K 101.73% | -266K 204.31% | |
other non cash items | 39K - | 2K 94.87% | 5.14M 256,750% | 48K 99.07% | 898K 1,770.83% | 1.14M 27.39% | -103K 109.00% | |
net cash provided by operating activities | 8.24M - | -16.25M 297.30% | -36.71M 125.89% | -50.91M 38.68% | -69.13M 35.80% | -86.69M 25.39% | -75.79M 12.57% | |
investments in property plant and equipment | -573K - | -414K 27.75% | -3.20M 673.67% | -1M 68.78% | -9.11M 811% | -11.54M 26.63% | -2.77M 75.98% | |
acquisitions net | 9.11M - | 11.54M 26.63% | 2.77M 75.98% | |||||
purchases of investments | -168.57M - | -153.31M 9.05% | -54.80M 64.25% | |||||
sales maturities of investments | 8.22M - | 5M - | 147.80M 2,855.98% | 173.29M 17.25% | ||||
other investing activites | 24K - | -9.11M - | -11.54M 26.63% | -2.77M 75.98% | ||||
net cash used for investing activites | 7.67M - | -414K 105.39% | -3.20M 673.67% | -1M 68.78% | -172.68M 17,168% | -17.05M 90.13% | 115.72M 778.69% | |
debt repayment | ||||||||
common stock issued | 16K - | 105K 556.25% | 75K 28.57% | 205.66M 274,110.67% | 114.30M 44.42% | 2.73M 97.61% | 156.83M 5,644.76% | |
common stock repurchased | -278.13M - | |||||||
dividends paid | ||||||||
other financing activites | 84.47M - | -2.27M 102.69% | 351.45M 15,582.42% | 3.79M 98.92% | 355K 90.64% | |||
net cash used provided by financing activities | 16K - | 84.58M 528,506.25% | -2.19M 102.60% | 278.98M 12,809.93% | 118.09M 57.67% | 3.08M 97.39% | 156.83M 4,983.70% | |
effect of forex changes on cash | ||||||||
net change in cash | 15.93M - | 67.91M 326.36% | -42.11M 162.01% | 227.07M 639.25% | -123.72M 154.49% | -100.65M 18.65% | 196.76M 295.49% | |
cash at beginning of period | 7.92M - | 23.85M 201.06% | 91.76M 284.74% | 49.65M 45.89% | 276.73M 457.33% | 153.00M 44.71% | 52.35M 65.78% | |
cash at end of period | 23.85M - | 91.76M 284.74% | 49.65M 45.89% | 276.73M 457.33% | 153.00M 44.71% | 52.35M 65.78% | 249.11M 375.84% | |
operating cash flow | 8.24M - | -16.25M 297.30% | -36.71M 125.89% | -50.91M 38.68% | -69.13M 35.80% | -86.69M 25.39% | -75.79M 12.57% | |
capital expenditure | -573K - | -414K 27.75% | -3.20M 673.67% | -1M 68.78% | -9.11M 811% | -11.54M 26.63% | -2.77M 75.98% | |
free cash flow | 7.66M - | -16.67M 317.46% | -39.91M 139.49% | -51.91M 30.05% | -78.24M 50.73% | -98.22M 25.53% | -78.56M 20.01% |
All numbers in USD (except ratios and percentages)